Try our mobile app

BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set

Published: 2021-01-10 23:44:00 ET
<<<  go to BMRN company page

- Significantly Reduced Mean Annualized Bleeding Rate by 84% (p-value